TY - JOUR T1 - The advanced development of molecular targeted therapy for hepatocellular carcinoma JF - Cancer Biology & Medicine JO - Cancer Biology & Medicine SP - 802 LP - 817 DO - 10.20892/j.issn.2095-3941.2021.0661 VL - 19 IS - 6 AU - Tao Yan AU - Lingxiang Yu AU - Ning Zhang AU - Caiyun Peng AU - Guodong Su AU - Yi Jing AU - Linzhi Zhang AU - Tong Wu AU - Jiamin Cheng AU - Qian Guo AU - Xiaoliang Shi AU - Yinying Lu Y1 - 2022/06/15 UR - http://www.cancerbiomed.org/content/19/6/802.abstract N2 - Hepatocellular carcinoma (HCC), one of the most common malignant tumors in China, severely threatens the life and health of patients. In recent years, precision medicine, clinical diagnoses, treatments, and innovative research have led to important breakthroughs in HCC care. The discovery of new biomarkers and the promotion of liquid biopsy technologies have greatly facilitated the early diagnosis and treatment of HCC. Progress in targeted therapy and immunotherapy has provided more choices for precise HCC treatment. Multiomics technologies, such as genomics, transcriptomics, and metabolomics, have enabled deeper understanding of the occurrence and development mechanisms, heterogeneity, and genetic mutation characteristics of HCC. The continued promotion and accurate typing of HCC, accurate guidance of treatment, and accurate prognostication have provided more treatment opportunities and prolonged survival timelines for patients with HCC. Innovative HCC research providing an in-depth understanding of the biological characteristics of HCC will be translated into accurate clinical practices for the diagnosis and treatment of HCC. ER -